YB-800

N/A

Report date: 2024/12/17 17:25:19
First In Class

Base Information

Drug NameYB-800
Drug Alias NameYB-800
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsNeuronal pentraxin receptor inhibitors
TargetsNeuronal pentraxin receptor
Therapy Area/IndicationsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNagoya University
China Registration ClassN/A

Develop Information

Active CompaniesPaul Scherrer Institute,Villigen,SwitzerlandYmmunobio AG
Inactive CompaniesN/A
Active IndicationsGastrointestinal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A